Atrium Therapeutics (RNA) Fundamental Analysis: Revenue, Earnings & Valuation

4.14 / 10

Netural

Fundamental analysis yields a 4.14/10 score. Profit‑MV and Cash‑MV are positive, supporting profitability, whereas Asset‑MV and Revenue‑MV lag. Inventory turnover (106.6) and current‑asset turnover (11.19) are strong; gross margin hits 100%, but overall health remains modest.

Analysis Checks(8/10)

Revenue-MV

Value-0.08

Score1/3

Weight13.08%

1M Return5.44%

Inventory turnover ratio

Value106.57

Score3/3

Weight15.87%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.37%

1M Return1.67%

Profit-MV

Value0.68

Score2/3

Weight14.93%

1M Return6.36%

Income tax / Total profit (%)

Value0.29

Score3/3

Weight5.25%

1M Return2.26%

Current assets turnover ratio

Value11.19

Score3/3

Weight18.84%

1M Return7.57%

Fixed assets turnover ratio

Value3.05

Score2/3

Weight0.02%

1M Return0.01%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight7.89%

1M Return4.08%

Asset-MV

Value-0.55

Score0/3

Weight6.13%

1M Return2.73%

Cash-MV

Value0.03

Score2/3

Weight14.63%

1M Return6.19%

Is RNA fundamentally strong?

RNA scores 4.14/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -265.88% net margin, -41.03 P/E ratio, -32.38 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.